Stephen N. Davis

University of Maryland, Baltimore — United States

Medicine · Health Sciences

56h-index17.6kcitations253works1.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Diabetes Management and Research(160), Pancreatic function and diabetes(79), Diabetes Treatment and Management(70), Diabetes and associated disorders(47), Heart Rate Variability and Autonomic Control(39)

Publications253 total

What is our current understanding of insulin-derived amyloidosis?
Expert Opinion on Drug Safety·2025
A safety review of approved oral agents for treating type 2 diabetes and associated diseases in pregnant patients
Expert Opinion on Drug Safety·2025
Treatment of diabetes in patients with advanced chronic kidney disease or kidney failure
Nephrology Dialysis Transplantation·2025· 1 cited
Hypoglycemia
Elsevier eBooks·2025
Evaluating semaglutide + LAI-287 (IcoSema) for the treatment of diabetes mellitus type II
Expert Opinion on Pharmacotherapy·2024· 1 cited
Drugs stimulating insulin secretion in early clinical development for the treatment of type 1 diabetes: what’s new?
Expert Opinion on Investigational Drugs·2024
Is metformin safe in pregnancy: a focus on offspring outcomes
Expert Opinion on Drug Safety·2024· 6 cited
How close are we to personalized pharmacotherapies and innovative technology for type 1 diabetes management?
Expert Opinion on Pharmacotherapy·2023Open Access
Type 1 diabetes: key drug targets and how they could influence future therapeutics
Expert Opinion on Therapeutic Targets·2023· 4 cited
Contributors
Elsevier eBooks·2023
Diabetic autonomic dysfunction
Elsevier eBooks·2023
Emerging drugs for the treatment of diabetic nephropathy
Expert Opinion on Emerging Drugs·2022· 22 cited
The role of Recent Pharmacotherapeutic Options on the Management of Treatment Resistant Type 2 Diabetes
Expert Opinion on Pharmacotherapy·2022· 4 cited
Nocturnal hypoglycemia in type 1 and type 2 diabetes: an update on prevalence, prevention, pathophysiology and patient awareness
Expert Review of Endocrinology & Metabolism·2021· 19 cited
Sodium–glucose cotransporter 2 inhibitors for the management of type 2 diabetes
Expert Opinion on Pharmacotherapy·2021· 2 cited
Update on the effects of GLP-1 receptor agonists for the treatment of polycystic ovary syndrome
Expert Review of Clinical Pharmacology·2021· 68 cited
Effects of anti-diabetic treatments in type 2 diabetes and fatty liver disease
Expert Review of Clinical Pharmacology·2021· 11 cited
Medical–Dental Integration in a Rural Community Health Center: A Qualitative Program Evaluation
Health Promotion Practice·2021· 6 cited
Effects of Sensor-Augmented Pump Therapy on Glycemic Variability in Well-Controlled Type 1 Diabetes in the STAR 3 Study
UNC Libraries·2020Open Access
Sensor-Augmented Pump Therapy for A1C Reduction (STAR 3) Study: Results from the 6-month continuation phase
UNC Libraries·2020· 3 citedOpen Access
page 1 of 13Next →

Frequent Co-authors

Donna B. Tate(13), Pietro Galassetti(9), Andrew C. Ertl(7), David H. Wasserman(6), Alan D. Cherrington(6), Ray A. Neill(5), C. Shavers(4), Stephnie Mann(4), William C. Duckworth(3), Domenic J. Reda(3), Nicholas Emanuele(3), Peter D. Reaven(3), Rodney A. Hayward(3), Nino G. Joy(3), Maka S. Hedrington(3), Vanessa Jones Briscoe(3), Fernando Costa(3), Filipa Alves da Costa(3), Darleen A. Sandoval(3), Lisa M. Younk(3)